Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer
Authors:
- L. ProvenzanoLPL. Provenzano
- M. FavaliMFM. Favali
- L. MazzeoLML. Mazzeo
- A. SpagnolettiASA. Spagnoletti
- M. RuggirelloMRM. Ruggirello
- G. CalaresoGCG. Calareso
- F.G. GrecoFGF.G. Greco
- R. VigoritoRVR. Vigorito
- A. QuartaAQA. Quarta
- F. CalimeriF. Calimeri
- M. MonteleoneMMM. Monteleone
- G. BaselliG. Baselli
Open Access
- 23 September 2025
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Abstract
No abstract availableFunding Information
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
- Ministry of Health
This publication has 32 references indexed in Scilit:
- APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchClinical Lung Cancer, 2023
- Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic reviewAnnals of Oncology, 2023
- The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With ImmunotherapyClinical Lung Cancer, 2023
- Structural and functional radiomics for lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Application of radiomics features selection and classification algorithms for medical imaging decision: MRI radiomics breast cancer cases studyInformatics in Medicine Unlocked, 2021
- Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AIInformation Fusion, 2020
- Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancerEuropean Journal of Cancer, 2019
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyJAMA Oncology, 2018
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009